Onyx Pharma - ASCO ’12: Kyprolis’ Data enough to obtain an ‘Accelerate Approval’?
Efficacy and pooled safety data from the four PhII trials of Kyprolis (carfilzomib – CFZ, R, next-generation proteasome inhibitor) @ SCO ’12 highlight the potential of CFZ in Newly Diagnosed Multiple Myeloma – NDMM and Relapsed and Refractory Multiple Myeloma – R/R MM pts. Positive verdict from upcoming advisory committee (June 20, 2012) and PDUFA (PDUFA: July 27, 2012 for R/R MM) of CFZ keep ONXX’s shares volatile. If the drug be approved in July or receives a positive review from the advisory group (vs. consensus’ expectation of approval in 2014) could… For more details, please read our report released on May 31st, 2012 on ONXX, titled “ASCO ’12: Kyprolis’ Data enough to obtain an ‘Accelerate Approval’?”
COMPANIES MENTIONED
ONXX
ONXX
